Identification of a Ten-Gene Signature of DNA Damage Response Pathways with Prognostic Value in Esophageal Squamous Cell Carcinoma

Figure 6

DRGS is a prognostic biomarker and predicts immunotherapy efficacy. Subgroup analyses estimating the prognostic value of DRGS in (a) pan-cancers from TCGA data sets. The Kaplan–Meier survival curves of overall survival in (b) the Liu2019 cohort, (e) the IMvigor210 cohort, and (h) the GSE78220 cohort. Rate of CR/PR and SD/PD to anti-PD-L1 immunotherapy in the high or low group in (c) the Liu2019 cohort, (f) the IMvigor210 cohort, and (i) the GSE78220 cohort. Distribution of DRGS scores with different anti-PD-L1 clinical responses in (d) the Liu2019 cohort, (g) the IMvigor210 cohort, and (j) the GSE78220 cohort. The values represent the mean value. The differences among groups were compared using the Kruskal–Wallis test.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)